Abstract
Artificial oxygen carriers aim at improving oxygen delivery (DO2). Artificial oxygen carriers, therefore, may be used as an alternative to allogeneic blood transfusions or to improve tissue oxygenation and function of organs with marginal oxygen supply [1, 2]. Modified hemoglobin solutions and perfluorocarbon (PFC) emulsions are currently undergoing clinical testing. This chapter is based on a recent review article [3] where more detailed references may be found. Current knowledge of artifical oxygen carriers is based on published data from approximately 500–1000 patients treated with these compounds and a similar number of control patients. Unfortunately, there is still a significant amount of non-published data that renders the overall assessment of these solutions difficult.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Spahn DR, Pasch T (2001) Physiological properties of blood substitutes. News Physiol Sci 16: 38–41
Winslow RM (2000) Blood substitutes. Advanced Drug Delivery Reviews 40: 131–142
Spahn DR, Kocian R (2003) Place of artifical oxygen carriers in reducing allogeneic blood transfusions and augmenting tissue oxygenation. Can J Anaesth (in press)
Stowell CP, Levin J, Spiess BD, Winslow RM (2001) Progress in the development of RBC substitutes. Transfusion 41: 287–299
Viele MK, Weiskopf RB, Fisher D (1997) Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology 86: 848–858
Winslow RM (2000) Alpha-alpha-crosslinked hemoglobin: was failure predicted by preclinical testing? Vox Sang 79: 1–20
Sloan EP, Koenigsberg M, Gens D, et al (19999) Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 282: 1857–1864
Lamy ML, Daily EK, Brichant J-F, et al (2000) Randomized trial of Diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. Anesthesiology 92: 646–656
Gould SA, Moore EE, Hoyt DB, et al (1998) The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 187: 113–120
Carmichael FJ, Biro GP, Cheng DC (2001) Phase III clinical trial of hemolink in conjunction with intraoperative autologous donation (IAD) in cardiac surgical patients. Artif Cells Blood Substit Immobil Biotechnol 29: 102 (abst)
Jahr JS (2001) A novel blood substitute: Use of HBOC-201 (Hemopure) to decrease need for RBC: Results of pivotal trail in orthopedic surgery patients. Crit Care Med 29 (suppl): A160 (abst)
Levy JH, Goodnough LT, Greilich P, et al (2002) Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg 124: 35–42
Cheng DC, Martineau R, MacAdams C, et al (2001) Safety of Hemolink as an oxygen therapeutic in patients undergoing coronary artery bypass graft surgery. Anesth Analg 92 (suppl):SCA3 (abst)
Jahr JS, Stewart LM, MacKenzie C, Bourke D, williams JP (2002) Pivotal phase III study: safety of polymerized bovine hemoglobin (HBOC-201, Hemopure) as compared to RBC in patients undergoing orthopedic surgery. Anesthesiology 96: A243 (abst)
Sprung J, Kindscher JD, Wahr JA, et al (2002) The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized single-blind study. Anesth Analg 94: 799–808
Riess JG (2001) Oxygen carriers (“Blood substitutes”)–raison d’etre, chemistry, and some physiology. Chem Rev 101: 2797–2920
Keipert PE, Faithfull NS, Bradley JD, et al (1994) Oxygen delivery augmentation by low-dose perfluorochemical emulsion during profound normovolemic hemodilution. Adv Exp Med Biol 345: 197–204
Spahn DR, van Bremt R, Theilmeier G, et al (1999) Perflubron emulsion delays blood transfusion in orthopedic surgery. Anesthesiology 91: 1195–1208
Frumento RJ, Mongero LM, Naka Y, Bennett Guerrero E (2002) Preserved gastric tono-metric variables in cardiac surgical patients administered intravenous perflubron emulsion. Anesth Analg 94: 809–814
Spahn DR, Waschke K, Standl T, et al (2002) Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology 96: 1338–1349
Looker D, Abbott-Brown D, Cozart P, et al (1992) A human recombinant haemoglobin designed for use as a blood substitute. Natue 356: 258–260
Spahn DR (1999) Blood substitutes: artifical oxygen carriers: perfluorocarbon emulsions. Crit Care 3: R93 - R97
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Dettori, N., Kocian, R., Spahn, D.R. (2003). Clinical Use of Artificial Oxygen Carriers. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-5548-0_58
Download citation
DOI: https://doi.org/10.1007/978-1-4757-5548-0_58
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4757-5550-3
Online ISBN: 978-1-4757-5548-0
eBook Packages: Springer Book Archive